News

BIOASIS TECHNOLOGIES announced that Dr. Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, has been appointed as chair of the board of directors. She takes over from former board chair…
Read More...

Symbiotix Biotherapies announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix gains access to a portfolio of intellectual…
Read More...

Saladax Biomedical Inc., a diagnostics company providing kits to test drug levels for adherence and personalized dose management, announced that it has received CE mark (Conformité…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the…
Read More...

CureVac AG announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to CureVac on GMP-conforming pharmaceutical manufacturing methods for producing RNA,…
Read More...

Biocom, the association representing the life science industry of California, concluded its Regenerative Medicine Advocacy Fly-In to Washington, D.C. yesterday, the culmination of…
Read More...

vTv Therapeutics Inc. announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of…
Read More...

Aldevron has selected AES Clean Technology to design modular cleanrooms for Aldevron’s $30 million, 70,000 square-foot manufacturing facility in Fargo, N.D. Cleanroom construction is…
Read More...

Thermo Fisher Scientific announced that it is expanding its footprint in the European Union and investing $35 million in a state-of-the-art pharma services supply chain facility in…
Read More...

Pfizer and Astellas Pharma announced that a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) has been accepted for filing and granted Priority Review designation by…
Read More...

Ionis Pharmaceuticals and Akcea Therapeutics, Inc., an affiliate of Ionis, announced an exclusive, worldwide license by Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly…
Read More...

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement,…
Read More...

Intezyne announced that it has partnered with Exosome Diagnostics, a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics, to design…
Read More...

Mallinckrodt plc announced it has closed the sale of RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant to Baxter International Inc. "This action further…
Read More...

Ardelyx, Inc. announced a license agreement with Knight Therapeutics, Inc. (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is…
Read More...

Nexcelom Bioscience announced that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom's worldwide growth…
Read More...

Global pharmaceutical company Mylan N.V. announced the U.S. launch of the oncology drug Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials, a generic…
Read More...

Akcea Therapeutics United Kingdom (UK) Ltd announced that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the UK’s…
Read More...

Kalytera Therapeutics announced that it has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been…
Read More...

Standardizing and personalizing insulin therapy management for hospitalized patients is a goal Piedmont Healthcare is poised to achieve through expanded use of Glytec’s eGlycemic…
Read More...